TSUNG-CHIEN LUChu P.-L.CHI-SHIN WUTsai K.-C.WEN-JONE CHEN2020-02-272020-02-2720060929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/466205Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse reaction to neuroleptics, which is characterized by hyperthermia, extrapyramidal symptoms, altered consciousness and autonomic dysfunction. Although NMS is most commonly induced by the high-potency neuroleptics, its development has also been associated with the use of non-neuroleptic agents that block central dopamine pathways. A 68-year-old man with generalized anxiety disorder and depressive symptoms presented at the emergency department (ED) with high fever, tremor, muscle rigidity, rhabdomyolysis and altered mental status. NMS was considered to have been caused by the recent addition and subsequent dose increase in his treatment regimen of venlafaxine, a serotonin norepinephrine reuptake inhibitor. He was successfully treated with bromocriptine, lorazepam, and fluid hydration in the ED and intensive care unit. ?2006 Elsevier & Formosan Medical Association.[SDGs]SDG3alanine aminotransferase; amantadine; aspartate aminotransferase; bromocriptine; buspirone; clonazepam; creatine kinase; fluoxetine; lorazepam; lysine acetylsalicylate; paracetamol; propranolol; trazodone; venlafaxine; aged; alanine aminotransferase blood level; alkalinization; article; aspartate aminotransferase blood level; case report; clinical feature; diagnostic and statistical manual of mental disorders; differential diagnosis; disease exacerbation; drug megadose; drug substitution; fever; fluid therapy; generalized anxiety disorder; human; hydration; intensive care unit; leukocyte count; limb tremor; male; muscle rigidity; neuroleptic malignant syndrome; neurologic examination; parkinsonism; treatment outcomejournal article10.1016/S0929-6646(09)60115-7164400772-s2.0-31144473132